Enforcement Analysis — Veritas Quality Consultants https://www.veritasqualityconsultants.com/enforcement-analysis/ Weekly analysis of FDA warning letters: what the observation said, what the firm proposed in its Form 483 response, why FDA found that response inadequate, and what a defensible answer would have required. en Copyright Veritas Quality Consultants, LLC Mon, 24 Aug 2026 00:00:00 +0000 1440 https://www.veritasqualityconsultants.com/enforcement-analysis/assets/veritas-lockup-color.png Enforcement Analysis — Veritas Quality Consultants https://www.veritasqualityconsultants.com/enforcement-analysis/ “A sample of other CGMP records” — how FDA sizes a retrospective review https://www.veritasqualityconsultants.com/enforcement-analysis/issue-09-retrospective-review-scope.html https://www.veritasqualityconsultants.com/enforcement-analysis/issue-09-retrospective-review-scope.html Mon, 24 Aug 2026 00:00:00 +0000 A firm found fourteen more affected batches than FDA did and invalidated all sixteen sterility tests. FDA still rejected the response, because a review scoped by sampling cannot find the edge of the problem. Enforcement Analysis “Repeated failures demonstrate that executive management oversight … is inadequate” — when a finding leaves the quality unit https://www.veritasqualityconsultants.com/enforcement-analysis/issue-08-repeat-observations-executive-management.html https://www.veritasqualityconsultants.com/enforcement-analysis/issue-08-repeat-observations-executive-management.html Tue, 18 Aug 2026 00:00:00 +0000 Four inspections in seven years cited the same cleaning deficiencies. Why a repeat observation changes who has to answer, and what that answer must contain. Enforcement Analysis “May be retested” — when your acceptance criteria are wide enough to absorb the failure https://www.veritasqualityconsultants.com/enforcement-analysis/issue-07-acceptance-criteria-retest-until-pass.html https://www.veritasqualityconsultants.com/enforcement-analysis/issue-07-acceptance-criteria-retest-until-pass.html Mon, 10 Aug 2026 00:00:00 +0000 Three years of validation cycles passed with biological indicator growth in nearly every one. FDA’s finding was not the growth. It was the limit that kept calling it a pass. Enforcement Analysis “Only at your customer’s request” — who owns testing scope at a contract manufacturer https://www.veritasqualityconsultants.com/enforcement-analysis/issue-06-contract-manufacturer-testing-scope.html https://www.veritasqualityconsultants.com/enforcement-analysis/issue-06-contract-manufacturer-testing-scope.html Mon, 03 Aug 2026 00:00:00 +0000 A batch released with no microbiological testing, because no customer had asked for it. FDA’s answer: a purchase request is not a specification. Enforcement Analysis “We acknowledge your retraining” — the sentence FDA writes before rejecting your CAPA https://www.veritasqualityconsultants.com/enforcement-analysis/issue-05-retraining-as-corrective-action.html https://www.veritasqualityconsultants.com/enforcement-analysis/issue-05-retraining-as-corrective-action.html Tue, 28 Jul 2026 00:00:00 +0000 Six corrective actions built on retraining, six rejections, and the same four reasons in rotation. What training alone can never supply. Enforcement Analysis “The quality unit approved the release” — how FDA measures quality unit authority https://www.veritasqualityconsultants.com/enforcement-analysis/issue-04-quality-unit-authority.html https://www.veritasqualityconsultants.com/enforcement-analysis/issue-04-quality-unit-authority.html Mon, 27 Jul 2026 00:00:00 +0000 Insect larvae on an ISO 5 monitoring plate, a risk rating of low, and a released lot. FDA read the disposition itself as proof the quality unit was not exercising its authority. Enforcement Analysis “Contamination occurred during handling” — the OOS reflex FDA keeps rejecting https://www.veritasqualityconsultants.com/enforcement-analysis/issue-03-oos-invalidation.html https://www.veritasqualityconsultants.com/enforcement-analysis/issue-03-oos-invalidation.html Tue, 21 Jul 2026 00:00:00 +0000 A failing result, no organism identified, a passing resample, and a released lot. FDA rejected the invalidation because a resample that passes is not a root cause. Enforcement Analysis “You have unsuccessfully attempted similar corrective actions in the past” — when your CAPA history becomes the finding https://www.veritasqualityconsultants.com/enforcement-analysis/issue-02-repeat-capa-failure.html https://www.veritasqualityconsultants.com/enforcement-analysis/issue-02-repeat-capa-failure.html Mon, 20 Jul 2026 00:00:00 +0000 A firm listed its prior corrective actions to demonstrate diligence. FDA read the same list as proof its CAPA system could not detect its own ineffectiveness. Enforcement Analysis “The operator didn’t follow procedure” — why that sentence cost one firm a warning letter https://www.veritasqualityconsultants.com/enforcement-analysis/issue-01-operator-root-cause.html https://www.veritasqualityconsultants.com/enforcement-analysis/issue-01-operator-root-cause.html Mon, 20 Jul 2026 00:00:00 +0000 Three findings, three attributions to individual error, three rejections. The firm’s own written procedure had directed the behaviour it blamed on the analyst. Enforcement Analysis